Search

Saumya Pant

from West Windsor, NJ
Age ~45
Get Report
Related to:
Hina Pant, 42Niraj K Pant, 51
Connected to:
Alok Pant, 52Anju P Pant, 49Karuna Pant, 47Mamata Pant, 49Mondira D Pant, 51Muktesh Pant, 79Nitin Pant, 47Pooja Pant, 46Prakash Pant, 82Rummy Pant, 55

Saumya Pant Phones & Addresses

  • West Windsor, NJ
  • Princeton, NJ
  • Edison, NJ
  • Piscataway, NJ
  • Williston Park, NY
  • Oviedo, FL
  • 111 Dorothy Ave, Edison, NJ 08837

Publications

Us Patents

Methods Of Identifying A Subject Suitable For An Immuno-Oncology (I-O) Therapy

View page
US Patent:
20220259669, Aug 18, 2022
Filed:
May 29, 2020
Appl. No.:
17/615533
Inventors:
- Princeton NJ, US
Lan ZHANG - Princeton NJ, US
Keyur H. DESAI - Princeton NJ, US
Neeraj ADYA - Princeton NJ, US
Zhenhao QI - Princeton NJ, US
Alex GREENFIELD - Princeton NJ, US
George C. LEE - Princeton NJ, US
Scott Adams ELY - Princeton NJ, US
Saumya PANT - Princeton NJ, US
George A. GREEN - Newton NJ, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
C12Q 1/6886
C07K 16/28
G01N 33/68
Abstract:
The present disclosure provides methods of identifying a subject suitable for an immunooncology (I-O) therapy comprising measuring the expression of one or more of STAT1, IFNγ, NECTIN2, and CSFIR. In some aspects, the I-O therapy comprises administering an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof to the subject.

Cell Localization Signature And Combination Therapy

View page
US Patent:
20220233691, Jul 28, 2022
Filed:
May 29, 2020
Appl. No.:
17/615536
Inventors:
- Princeton NJ, US
Lan ZHANG - Princeton NJ, US
Keyur H. DESAI - Princeton NJ, US
Neeraj ADYA - Princeton NJ, US
Zhenhao QI - Princeton NJ, US
Alex GREENFIELD - Princeton NJ, US
George C. LEE - Princeton NJ, US
Scott Adams ELY - Princeton NJ, US
Saumya PANT - Princeton NJ, US
George A. GREEN - Newton NJ, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 39/395
A61P 35/04
A61K 45/06
G01N 33/574
C12Q 1/6886
Abstract:
The present disclosure provides methods of identifying a subject suitable for an immuno-oncology (I-O) therapy comprising measuring the expression of one or more of STAT1, IFNγ, NECTIN2, and CSF1R. In some aspects, the I-O therapy comprises administering an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof to the subject.

Multi-Tumor Gene Signature For Suitability To Immuno-Oncology Therapy

View page
US Patent:
20220363760, Nov 17, 2022
Filed:
May 29, 2020
Appl. No.:
17/615535
Inventors:
- Princeton NJ, US
Lan ZHANG - Princeton NJ, US
Keyur H. DESAI - Princeton NJ, US
Neeraj ADYA - Princeton NJ, US
Zhenhao QI - Princeton NJ, US
Kim ZERBA - Princeton NJ, US
Scott Adams ELY - Princeton NJ, US
Saumya PANT - Princeton NJ, US
George A. GREEN - Newton NJ, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
C07K 16/28
A61P 35/00
C12Q 1/6886
G01N 33/574
Abstract:
The present disclosure provides methods of identifying a subject suitable for an immunooncology (I-O) therapy comprising measuring the expression of one or more genes of a pantumor inflammation gene panel. In some aspects, the method further comprises administering an I-O therapy to the subject. In some aspects, the I-O therapy comprises administering an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof to the subject.
Control profile
Saumya Pant from West Windsor, NJ, age ~45 Get Report